WO2010019952A3 - Methods and systems for predicting response of cells to a therapeutic agent - Google Patents

Methods and systems for predicting response of cells to a therapeutic agent Download PDF

Info

Publication number
WO2010019952A3
WO2010019952A3 PCT/US2009/054051 US2009054051W WO2010019952A3 WO 2010019952 A3 WO2010019952 A3 WO 2010019952A3 US 2009054051 W US2009054051 W US 2009054051W WO 2010019952 A3 WO2010019952 A3 WO 2010019952A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
methods
nas
treatment
therapeutic agent
Prior art date
Application number
PCT/US2009/054051
Other languages
French (fr)
Other versions
WO2010019952A2 (en
Inventor
Birgit Schoeberl
Brian Harms
Francis David Gibbons
Jonathan Basil Fitzgerald
Matthew David Onsum
Ulrik Nielsen
William Kubasek
Original Assignee
Merrimack Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41228727&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2010019952(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CA2732658A priority Critical patent/CA2732658A1/en
Priority to JP2011523216A priority patent/JP2012500008A/en
Priority to US13/058,687 priority patent/US8623592B2/en
Priority to ES09791584T priority patent/ES2433424T3/en
Priority to BRPI0917871A priority patent/BRPI0917871A2/en
Priority to UAA201101792A priority patent/UA104868C2/en
Priority to EP09791584.7A priority patent/EP2318548B1/en
Application filed by Merrimack Pharmaceuticals, Inc. filed Critical Merrimack Pharmaceuticals, Inc.
Priority to AU2009281721A priority patent/AU2009281721A1/en
Priority to EA201100373A priority patent/EA022884B1/en
Priority to KR1020117005954A priority patent/KR20110044905A/en
Priority to MX2011001764A priority patent/MX2011001764A/en
Priority to NZ591137A priority patent/NZ591137A/en
Priority to CN2009801404673A priority patent/CN102224255A/en
Priority to US12/707,521 priority patent/US20110027291A1/en
Publication of WO2010019952A2 publication Critical patent/WO2010019952A2/en
Publication of WO2010019952A3 publication Critical patent/WO2010019952A3/en
Priority to IL210865A priority patent/IL210865A/en
Priority to ZA2011/00921A priority patent/ZA201100921B/en
Priority to TN2011000069A priority patent/TN2011000069A1/en
Priority to MA33695A priority patent/MA32630B1/en
Priority to HK11109930.1A priority patent/HK1155782A1/en
Priority to US14/148,379 priority patent/US20140127238A1/en
Priority to US15/384,664 priority patent/US20170307631A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention provides methods for treating patients which methods comprise methods for predicting responses of cells, such as tumor cells, to treatment with therapeutic agents. These methods involve measuring, in a sample of the cells, levels of one or more components of a cellular network and then computing a Network Activation State (NAS) or a Network Inhibition State (NIS) for the cells using a computational model of the cellular network. The response of the cells to treatment is then predicted based on the NAS or NIS value that has been computed. The invention also comprises predictive methods for cellular responsiveness in which computation of a NAS or NIS value for the cells (e.g., tumor cells) is combined with use of a statistical classification algorithm. Biomarkers for predicting responsiveness to treatment with a therapeutic agent that targets a component within the ErbB signaling pathway are also provided.
PCT/US2009/054051 2008-08-15 2009-08-17 Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response WO2010019952A2 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
KR1020117005954A KR20110044905A (en) 2008-08-15 2009-08-17 Methods and systems for predicting cell response to therapeutic agents
MX2011001764A MX2011001764A (en) 2008-08-15 2009-08-17 Methods and systems for predicting response of cells to a therapeutic agent.
US13/058,687 US8623592B2 (en) 2008-08-15 2009-08-17 Methods and systems for predicting response of cells to a therapeutic agent
ES09791584T ES2433424T3 (en) 2008-08-15 2009-08-17 Methods and systems to predict cell response to a therapeutic agent
BRPI0917871A BRPI0917871A2 (en) 2008-08-15 2009-08-17 anti-erbb3 therapeutic agent for use in tumor therapy, methods for predicting tumor responsiveness of an anti-erbb3 therapeutic agent, for selecting anti-erbb3 therapy for a patient, for predicting cell response to treatment with a therapeutic agent , to identify a biomarker, and to prevent administration of an anti-erbb3 cancer drug, and kit to predict cell response to treatment with a therapeutic agent
UAA201101792A UA104868C2 (en) 2008-08-15 2009-08-17 Method for treating patient having neoplastic tumor according to predicted reaction
EP09791584.7A EP2318548B1 (en) 2008-08-15 2009-08-17 Methods and systems for predicting response of cells to a therapeutic agent
JP2011523216A JP2012500008A (en) 2008-08-15 2009-08-17 Methods and systems for predicting cellular responses to therapeutic agents
AU2009281721A AU2009281721A1 (en) 2008-08-15 2009-08-17 Methods and systems for predicting response of cells to a therapeutic agent
EA201100373A EA022884B1 (en) 2008-08-15 2009-08-17 METHOD FOR TREATING NEOPLASTIC TUMOR USING ANTI-ErbB3 ANTIBODY
NZ591137A NZ591137A (en) 2008-08-15 2009-08-17 Methods and systems for predicting response of cells to a therapeutic agent
CA2732658A CA2732658A1 (en) 2008-08-15 2009-08-17 Methods and systems for predicting response of cells to a therapeutic agent
CN2009801404673A CN102224255A (en) 2008-08-15 2009-08-17 Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
US12/707,521 US20110027291A1 (en) 2008-08-15 2010-02-17 Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
IL210865A IL210865A (en) 2008-08-15 2011-01-25 Anti-erbb3 antibody for use in a method for treating a patient having a neoplastic tumor
ZA2011/00921A ZA201100921B (en) 2008-08-15 2011-02-04 Methods and systems for predicting response of cells to a therapeutic agent
TN2011000069A TN2011000069A1 (en) 2009-08-17 2011-02-11 Methods and systems for preicting response of cells to a therapeutic agent
MA33695A MA32630B1 (en) 2008-08-15 2011-03-11 Methods, systems and products to predict the response of cancer cells to a therapeutic agent, and treatment to a patient according to the expected response
HK11109930.1A HK1155782A1 (en) 2008-08-15 2011-09-21 Methods and systems for predicting response of cells to a therapeutic agent
US14/148,379 US20140127238A1 (en) 2008-08-15 2014-01-06 Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
US15/384,664 US20170307631A1 (en) 2008-08-15 2016-12-20 Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US18905308P 2008-08-15 2008-08-15
US61/189,053 2008-08-15
US19470208P 2008-09-30 2008-09-30
US61/194,702 2008-09-30
US20820609P 2009-02-20 2009-02-20
US61/208,206 2009-02-20
US17036709P 2009-04-17 2009-04-17
US61/170,367 2009-04-17

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US13/058,687 A-371-Of-International US8623592B2 (en) 2008-08-15 2009-08-17 Methods and systems for predicting response of cells to a therapeutic agent
US12/707,521 Continuation-In-Part US20110027291A1 (en) 2008-08-15 2010-02-17 Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
US14/148,379 Continuation US20140127238A1 (en) 2008-08-15 2014-01-06 Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response

Publications (2)

Publication Number Publication Date
WO2010019952A2 WO2010019952A2 (en) 2010-02-18
WO2010019952A3 true WO2010019952A3 (en) 2010-06-24

Family

ID=41228727

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/054051 WO2010019952A2 (en) 2008-08-15 2009-08-17 Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response

Country Status (24)

Country Link
US (4) US8623592B2 (en)
EP (1) EP2318548B1 (en)
JP (1) JP2012500008A (en)
KR (1) KR20110044905A (en)
CN (1) CN102224255A (en)
AU (1) AU2009281721A1 (en)
BR (1) BRPI0917871A2 (en)
CA (1) CA2732658A1 (en)
CO (1) CO6341654A2 (en)
CR (1) CR20110128A (en)
DO (1) DOP2011000054A (en)
EA (1) EA022884B1 (en)
EC (1) ECSP11010872A (en)
ES (1) ES2433424T3 (en)
HK (1) HK1155782A1 (en)
IL (1) IL210865A (en)
MA (1) MA32630B1 (en)
MX (1) MX2011001764A (en)
NZ (1) NZ591137A (en)
PE (1) PE20120015A1 (en)
SV (1) SV2011003840A (en)
UA (1) UA104868C2 (en)
WO (1) WO2010019952A2 (en)
ZA (1) ZA201100921B (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2129396T1 (en) 2007-02-16 2013-12-31 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
US8623592B2 (en) 2008-08-15 2014-01-07 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent
US8927694B2 (en) * 2008-11-18 2015-01-06 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
HUE029026T2 (en) 2009-12-22 2017-01-30 Roche Glycart Ag ANTI-HER3 Antibodies and uses thereof
PL2544680T3 (en) * 2010-03-11 2015-08-31 Merrimack Pharmaceuticals Inc Use of erbb3 inhibitors in the treatment of triple negative breast cancer
US20110318336A1 (en) * 2010-03-29 2011-12-29 George Mason Intellectual Properties, Inc. Identification and Treatment of Aggressive Lung Cancer Tumors
SG185366A1 (en) 2010-05-04 2012-12-28 Merrimack Pharmaceuticals Inc Antibodies against epidermal growth factor receptor (egfr) and uses thereof
WO2011159904A1 (en) * 2010-06-17 2011-12-22 The Trustees Of The University Of Pennsylvania Methods for predicting cellular signaling responses to combinatorial stimuli
TW201302793A (en) 2010-09-03 2013-01-16 Glaxo Group Ltd Novel antigen binding proteins
EP2635604B1 (en) 2010-11-01 2016-11-30 Symphogen A/S Pan-her antibody composition
SG193006A1 (en) 2011-03-02 2013-10-30 Berg Llc Interrogatory cell-based assays and uses thereof
EA201300996A1 (en) 2011-03-11 2014-01-30 Мерримак Фармасьютикалс, Инк. USE OF EGFR FAMILY RECEPTOR INHIBITORS IN THE TREATMENT OF THE BREAST-GROWTH CANCER
JP5588086B2 (en) 2011-04-19 2014-09-10 メリマック ファーマシューティカルズ インコーポレーティッド Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies
US8691231B2 (en) * 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
EP2530462A1 (en) * 2011-06-03 2012-12-05 Merrimack Pharmaceuticals, Inc. Methods and kits for predicting tumor responses to antibodies against epidermal growth factor receptor (EGFR) and uses thereof
AU2012294326A1 (en) * 2011-08-10 2013-03-21 Merrimack Pharmaceuticals, Inc. Treatment of advanced solid tumors using combination of anti-ErbB3 immunotherapy and selected chemotherapy
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
MX357391B (en) * 2011-09-30 2018-07-06 Regeneron Pharma Anti-erbb3 antibodies and uses thereof.
CN103959065B (en) * 2011-10-06 2018-07-17 Aveo制药公司 Predict the response of tumour confrontation ERBB3 antibody
AU2012335543C1 (en) 2011-11-09 2017-12-14 Beijing Cotimes Biotech Co., Ltd., HER3 antibodies and uses thereof
CN104160400A (en) * 2011-12-16 2014-11-19 克里帝奥成果技术公司 Programmable cell model for determining cancer treatments
CN108048521B (en) * 2012-04-02 2022-05-27 博格有限责任公司 Interrogative cell-based assays and uses thereof
EP2836482B1 (en) * 2012-04-10 2019-12-25 The Regents of The University of California Compositions and methods for treating cancer
CA2876636C (en) * 2012-06-13 2022-09-13 Medimmune, Llc Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies
KR101430309B1 (en) * 2012-11-14 2014-08-13 이선우 Bio 3D Modeling Device.
ES2971536T3 (en) * 2012-11-21 2024-06-05 Janssen Biotech Inc egfr/c-met bispecific antibodies
US10489717B2 (en) 2013-01-03 2019-11-26 Aetna, Inc. System and method for pharmacovigilance
US11424040B2 (en) * 2013-01-03 2022-08-23 Aetna Inc. System and method for pharmacovigilance
AR094403A1 (en) 2013-01-11 2015-07-29 Hoffmann La Roche ANTI-HER3 ANTIBODY COMBINATION THERAPY
KR20140093347A (en) * 2013-01-15 2014-07-28 삼성전자주식회사 Genes inducing agonistic effects by anti-c-Met antibody treatment and drug method using thereof
JP2016535079A (en) * 2013-09-30 2016-11-10 第一三共株式会社 Nucleic acid biomarkers and uses thereof
WO2015048804A2 (en) * 2013-09-30 2015-04-02 Daiichi Sankyo Co., Ltd. Protein biomarker and uses thereof
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
KR102456088B1 (en) 2014-04-04 2022-10-19 델 마 파마슈티컬스 Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
US20150285817A1 (en) * 2014-04-08 2015-10-08 Biodesix, Inc. Method for treating and identifying lung cancer patients likely to benefit from EGFR inhibitor and a monoclonal antibody HGF inhibitor combination therapy
MA39599A (en) 2014-05-14 2016-10-05 Merrimack Pharmaceuticals Inc Dosage and administration anti-egfr therapeutics
US10482385B2 (en) 2014-09-11 2019-11-19 Berg Llc Bayesian causal relationship network models for healthcare diagnosis and treatment based on patient data
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
CN107750165A (en) * 2015-04-17 2018-03-02 梅里麦克制药股份有限公司 By the combined therapy of class's soil monoclonal antibody in plug
GB201508841D0 (en) * 2015-05-22 2015-07-01 Isis Innovation Treatment
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
JP6382459B1 (en) * 2015-06-15 2018-08-29 ナントミクス，エルエルシー System and method for patient specific prediction of drug response from cell line genomics
JP6836586B2 (en) * 2015-09-29 2021-03-03 エイチティージー モレキュラー ダイアグノスティクス， インコーポレイテッド Methods for Subtyping Diffuse Large B-Cell Lymphoma (DLBCL)
EP3429623A1 (en) 2016-03-15 2019-01-23 Merrimack Pharmaceuticals, Inc. Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
EP3542290B1 (en) * 2016-11-17 2024-01-03 NantBio, Inc. Validation of inferred anticancer pathways
JP7404648B2 (en) 2019-04-25 2023-12-26 富士通株式会社 Therapeutic drug presentation method, therapeutic drug presentation device, and therapeutic drug presentation program
US20230088271A1 (en) * 2020-02-28 2023-03-23 The Board Of Trustees Of The Leland Stanford Junior University Systems and Methods for Determining Spatial Accumulation of Signaling Molecules Within Tissue Samples
WO2021240263A1 (en) 2020-05-26 2021-12-02 Insilico Medicine Ip Limited Biological data signatures of aging and methods of determining a biological aging clock
WO2022058980A1 (en) 2020-09-21 2022-03-24 Insilico Medicine Ip Limited Methylation data signatures of aging and methods of determining a methylation aging clock
CN113049249A (en) * 2020-12-31 2021-06-29 山东科技大学 Motor bearing fault diagnosis method and system

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035885A1 (en) * 1996-03-27 1997-10-02 Genentech, Inc. ErbB3 ANTIBODIES
WO2007015935A2 (en) * 2005-07-29 2007-02-08 Bayer Healthcare Llc Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy
WO2008100624A2 (en) * 2007-02-16 2008-08-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US6657103B1 (en) * 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5344760A (en) * 1991-06-03 1994-09-06 Ciba Corning Diagnostics Corp. Method of cancer detection
US6983227B1 (en) * 1995-01-17 2006-01-03 Intertech Ventures, Ltd. Virtual models of complex systems
US5968511A (en) * 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
CN1202247C (en) * 1996-07-12 2005-05-18 基因技术股份有限公司 Chimeric heteromultimer adhesins
US6255455B1 (en) * 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
US20020002276A1 (en) * 1997-02-10 2002-01-03 Genentech, Inc. Chimeric heteromultimer adhesins
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
GB2336695A (en) 1998-04-20 1999-10-27 Teamware Group Oy Modelling a work process
JP2002515511A (en) 1998-05-15 2002-05-28 イムクローン システムズ インコーポレイティド Treatment of human tumors using inhibitors of radiation and growth factor receptor tyrosine kinase
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
PL202369B1 (en) * 1999-08-27 2009-06-30 Genentech Inc DOSAGES FOR TREATMENT WITH ANTI−ErbB2 ANTIBODIES
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
DE60139768D1 (en) * 2000-05-19 2009-10-15 Genentech Inc GENERAL PROCESS FOR IMPROVING THE PROBABILITY OF AN EFFECTIVE RESPONSE TO A K
US20020119148A1 (en) * 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
US6871171B1 (en) * 2000-10-19 2005-03-22 Optimata Ltd. System and methods for optimized drug delivery and progression of diseased and normal cells
EP1228766A1 (en) * 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PYK2 phosphorylation by HER3 induces tumor invasion
WO2003011897A1 (en) * 2001-07-27 2003-02-13 The Regents Of The University Of California Modulation of heregulin and her3 interaction
US7662374B2 (en) 2001-08-03 2010-02-16 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbB family members and methods of use thereof
EP1421113A4 (en) * 2001-08-03 2005-04-13 Commw Scient Ind Res Org Methods of screening based on the egf receptor crystal structure
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
IL161430A0 (en) * 2001-10-19 2004-09-27 Pharma Mar Sa Pharmaceutical compositions containing ecteinascidin 743
US7415359B2 (en) * 2001-11-02 2008-08-19 Gene Network Sciences, Inc. Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents
EP1495123B1 (en) * 2002-03-26 2013-10-30 Zensun (Shanghai) Science and Technology Limited Erbb3 based methods and compositions for treating neoplasms
US20040248151A1 (en) * 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
US7332580B2 (en) * 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US20040229380A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
WO2004000102A2 (en) * 2002-06-19 2003-12-31 Abgenix, Inc. Method for predicting response to epidermal growth factor receptor-directed therapy
JP2006512895A (en) 2002-06-28 2006-04-20 ドマンティス リミテッド Ligand
BRPI0408928A (en) * 2003-04-01 2006-09-12 Monogram Biosciences Inc methods to determine a disease situation in a patient, an apoptotic situation of cells in a sample, and a cancer situation in a patient
CA2534898A1 (en) * 2003-08-08 2005-02-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US20070059785A1 (en) * 2003-08-15 2007-03-15 Smithkline Beecham Corporation Biomarkers in cancer
CN100559203C (en) * 2003-09-19 2009-11-11 Nxp股份有限公司 The electronic circuit that comprises secret submodule
US8554486B2 (en) * 2004-02-20 2013-10-08 The Mathworks, Inc. Method, computer program product, and apparatus for selective memory restoration of a simulation
BRPI0508286B8 (en) * 2004-03-31 2021-05-25 Dana Farber Cancer Inst Inc method to determine the likelihood of efficacy of an egfr tyrosine kinase inhibitor to treat cancer, use of an egfr tyrosine kinase inhibitor, probe, kit, and, primer pair
EP1778270A4 (en) * 2004-05-05 2009-09-02 Merrimack Pharmaceuticals Inc Bispecific binding agents for modulating biological activity
ES2553264T3 (en) * 2004-05-27 2015-12-07 The Regents Of The University Of Colorado Methods for predicting the clinical outcome for epidermal growth factor receptor inhibitors for cancer patients
WO2005121380A1 (en) * 2004-06-04 2005-12-22 Smithkline Beecham Corporation Predictive biomarkers in cancer therapy
WO2006017538A2 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
RU2410438C2 (en) * 2004-08-06 2011-01-27 Дженентек, Инк. Analyses and methods using biomarkers
AU2005272848A1 (en) 2004-08-12 2006-02-23 Dyax Corp. Tie complex binding proteins
US20060136139A1 (en) * 2004-10-12 2006-06-22 Elcock Adrian H Rapid computational identification of targets
WO2006044748A2 (en) 2004-10-15 2006-04-27 Monogram Biosciences, Inc. RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
RU2007135216A (en) 2005-02-23 2009-03-27 Мерримак Фармасьютикалз, Инк. (Us) BSPECIFIC BINDING AGENTS FOR MODULATION OF BIOLOGICAL ACTIVITY
WO2006096861A2 (en) * 2005-03-08 2006-09-14 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
WO2007041502A2 (en) 2005-09-30 2007-04-12 Monogram Biosciences Methods for determining responsiveness to cancer therapy
CA2624613A1 (en) 2005-10-05 2007-04-12 Astrazeneca Uk Limited Method to predict or monitor the response of a patient to an erbb receptor drug
AR056857A1 (en) 2005-12-30 2007-10-24 U3 Pharma Ag DIRECTED ANTIBODIES TO HER-3 (RECEIVER OF THE HUMAN EPIDERMAL GROWTH FACTOR-3) AND ITS USES
US7908091B2 (en) * 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
JP2009532393A (en) 2006-04-07 2009-09-10 コペンハーゲン ユニバーシティ ErbB receptor-derived peptide fragment
DK2032982T3 (en) 2006-05-05 2012-11-05 Univ Yale USE OF SUBCELLULAR LOCATION PROFILES AS PROGNOSTIC OR PREDICTIVE INDICATORS
EP2047262A4 (en) * 2006-07-13 2011-03-16 Univ Yale Methods for making cancer prognoses based on the subcellular localization of biomarkers
EP2097754B2 (en) 2006-11-28 2018-01-24 Daiichi Sankyo Europe GmbH Activated her3 as a marker for predicting therapeutic efficacy
US7825127B2 (en) * 2006-12-28 2010-11-02 Takeda Pharmaceutical Company, Limited Method for treating cancer
CL2008000614A1 (en) 2007-03-02 2008-09-05 Genentech Inc F Hoffmann La Ro METHOD TO TREAT A PATIENT WITH A TYPE OF CANCER THAT EXPRESSES THE HER3 RECEIVER AT A LOW LEVEL THROUGH THE ADMINISTRATION OF AN INHIBITOR OF THE HER DIMERIZATION.
DK2076289T3 (en) * 2007-04-13 2015-02-09 Dana Farber Cancer Inst Inc Methods for treating cancer resistance to ErbB drugs
US8623592B2 (en) 2008-08-15 2014-01-07 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035885A1 (en) * 1996-03-27 1997-10-02 Genentech, Inc. ErbB3 ANTIBODIES
EP1728802A2 (en) * 1996-03-27 2006-12-06 Genentech, Inc. ErbB3 antibodies
WO2007015935A2 (en) * 2005-07-29 2007-02-08 Bayer Healthcare Llc Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy
WO2008100624A2 (en) * 2007-02-16 2008-08-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ERJALA KAISA ET AL: "Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 JUL 2006, vol. 12, no. 13, 1 July 2006 (2006-07-01), pages 4103 - 4111, XP002554455, ISSN: 1078-0432 *
SCHOEBERL BIRGIT M ET AL: "Computational modeling and simulation lead to the development of MM-121, a human monoclonal antibody ErbB3 antagonist", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 49, 1 April 2008 (2008-04-01), pages 386, XP009125511, ISSN: 0197-016X *
SCHOEBERL BIRGIT M ET AL: "MM-121: a human monoclonal antibody ErbB3 antagonist", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 49, 1 April 2008 (2008-04-01), pages 944, XP009125512, ISSN: 0197-016X *

Also Published As

Publication number Publication date
US20170307631A1 (en) 2017-10-26
DOP2011000054A (en) 2011-04-30
WO2010019952A2 (en) 2010-02-18
KR20110044905A (en) 2011-05-02
HK1155782A1 (en) 2012-05-25
IL210865A0 (en) 2011-04-28
US8623592B2 (en) 2014-01-07
CR20110128A (en) 2011-09-27
CA2732658A1 (en) 2010-02-18
ZA201100921B (en) 2014-06-25
ES2433424T3 (en) 2013-12-11
MA32630B1 (en) 2011-09-01
EP2318548A2 (en) 2011-05-11
AU2009281721A1 (en) 2010-02-18
US20140127238A1 (en) 2014-05-08
NZ591137A (en) 2012-10-26
EP2318548B1 (en) 2013-10-16
CN102224255A (en) 2011-10-19
IL210865A (en) 2014-04-30
SV2011003840A (en) 2011-07-06
BRPI0917871A2 (en) 2017-06-20
CO6341654A2 (en) 2011-11-21
EA201100373A1 (en) 2011-08-30
US20110159513A1 (en) 2011-06-30
JP2012500008A (en) 2012-01-05
US20110027291A1 (en) 2011-02-03
EA022884B1 (en) 2016-03-31
PE20120015A1 (en) 2012-01-26
MX2011001764A (en) 2011-05-19
ECSP11010872A (en) 2011-09-30
UA104868C2 (en) 2014-03-25

Similar Documents

Publication Publication Date Title
WO2010019952A3 (en) Methods and systems for predicting response of cells to a therapeutic agent
WO2019213282A8 (en) Biomarkers for evaluating car-t cells to predict clinical outcome
WO2007061755A3 (en) Systems and methods to assess one or more body fluid metrics
BRPI0510617A (en) use of il-17 expression to predict skin inflammation; treatment processes
WO2007143211A3 (en) Methods for identifying agents and their use for the prevention of restenosis
WO2007092433A3 (en) Osteoporosis associated markers and methods of use thereof
WO2006125117A3 (en) Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
MX2009013410A (en) Biomarkers for predicting anti-tnf responsiveness or non-responsiveness.
WO2012118750A3 (en) Biological markers and methods for predicting response to b-cell antagonists
BR112013006764A2 (en) method for assessing a patient, kit, computer readable medium, method for assessing a treatment, method for assessing a patient's risk, method for monitoring, method for diagnosing, testing system, method for classifying or grouping a population of individuals, method for assessing a surrogate outcome, method for treating, use of at least one biomarker, use of an agent
WO2010018601A3 (en) Genetic variants predictive of cancer risk
WO2014169226A3 (en) Methods of diagnosing and treating chronic pain
WO2010068794A3 (en) Hif inhibitors and use thereof
EA201590630A1 (en) METHODS OF TREATMENT AND DIAGNOSTICS ASSOCIATED WITH LYZYLOXIDE-LIKE PROTEIN 2 (LOXL2)
GB0711327D0 (en) Diagnostic method
BR112012007555A2 (en) biomarkers to predict the sensitivity and response of ck2 protein kinase mediated diseases to ck2 inhibitors
WO2012018857A3 (en) Prediction of and monitoring cancer therapy response based on gene expression profiling
MX2009001070A (en) Use of melanoma inhibitory activity (mia) protein as an early indicator for therapeutic response in melanoma.
WO2012010871A3 (en) Systems and methods for medical data processing and analysis
WO2009022988A3 (en) Vhz for diagnosis and treatment of cancer
WO2012054915A3 (en) Homozygous and heterozygous idh1 gene-defective human astrocytoma cell lines
TN2011000069A1 (en) Methods and systems for preicting response of cells to a therapeutic agent
CA2699376C (en) Gene signature for the prediction of radiation therapy response
WO2008012692A3 (en) Assay for efficacy of histone deacetylase inhibitors
WO2013173085A3 (en) Methods and systems for predicting jamming effectiveness

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980140467.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09791584

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2732658

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009281721

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 13058687

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2011523216

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011000315

Country of ref document: CL

Ref document number: 591137

Country of ref document: NZ

Ref document number: 2011020254

Country of ref document: EG

ENP Entry into the national phase

Ref document number: 0125711

Country of ref document: KE

WWE Wipo information: entry into national phase

Ref document number: 000159-2011

Country of ref document: PE

Ref document number: MX/A/2011/001764

Country of ref document: MX

Ref document number: 12011500341

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 11018669

Country of ref document: CO

REEP Request for entry into the european phase

Ref document number: 2009791584

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009791584

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009281721

Country of ref document: AU

Date of ref document: 20090817

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1609/CHENP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: CR2011-000128

Country of ref document: CR

ENP Entry into the national phase

Ref document number: 20117005954

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201100373

Country of ref document: EA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: PI0917871

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110215